Outcomes After Nonresponse and Relapse Post-Tisagenlecleucel in Children, Adolescents, and Young Adults With B-Cell Acute Lymphoblastic Leukemia.
Liora M SchultzAnne A EatonChristina BaggottJenna RossoffSnehit PrabhuAmy K KeatingChrista KrupskiHolly L PacentaChristine L PhilipsJulie-An TalanoAmy MoskopSusanne H C BaumeisterGary Douglas MyersNicole A KarrasPatrick A BrownMuna QayedMichelle L HermistonPrakash SatwaniRachel WilcoxCara A RabikVanessa A FabrizioVasant ChinnabhandarMichael KunickiSharon MavroukakisEmily EgelerYimei LiCrystal L MackallKevin J CurranMichael R VernerisTheodore W LaetschHeather StefanskiPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
We describe poor survival across patients experiencing nonresponse to tisagenlecleucel. In the post-tisagenlecleucel relapse setting, patients can be salvaged; however, CD19- relapse is distinctly associated with decreased survival outcomes.